According to a new study, lithium appears to be safe and effective in treating bipolar disorder in children, at least in the short term.
A single dose of the psychedelic psilocybin reduces depression, anxiety, and feelings of hopelessness in cancer patients for 12 months after the drug is administered.
Researchers have identified six predictors that may help determine the correct amount of lithium to treat a patient with bipolar disorder.
A person's socioeconomic background may impact how well they respond to treatments for depression. Depressed people without a college degree had 9.8% less improvement in symptoms following treatment compared to graduates, and those who were unemployed had 6.6% less improvement than those with a steady job.
A new study reveals statins, biguanides and other drugs that help treat physical conditions may have significant benefits for the treatment of bipolar disorder and schizophrenia.
The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.
Researchers report the key why LSD hallucinations last so long is due to how it fits into serotonin receptors.
Researchers are testing a new method that could help find the best anti-depressants for individual patients more efficiently.
A new study reports intranasal delivery of ketamine may cause problematic side effects for some people with depression.
Study reveals those who microdosed psilocybin for 30 days showed greater improvements in mood, mental health, and psychomotor abilities than those who did not microdose. The findings have positive implications for the use of psychedelics to help treat mental health disorders.
Researchers say they have found no evidence LSD microdosing improves mood or cognitive function.